JP5688371B2 - マトリクスメタロプロテイナーゼ９（ｍｍｐ９）媒介状態を治療するための組成物および方法 - Google Patents

マトリクスメタロプロテイナーゼ９（ｍｍｐ９）媒介状態を治療するための組成物および方法 Download PDF

Info

Publication number
JP5688371B2
JP5688371B2 JP2011533355A JP2011533355A JP5688371B2 JP 5688371 B2 JP5688371 B2 JP 5688371B2 JP 2011533355 A JP2011533355 A JP 2011533355A JP 2011533355 A JP2011533355 A JP 2011533355A JP 5688371 B2 JP5688371 B2 JP 5688371B2
Authority
JP
Japan
Prior art keywords
fluid
mmp
composition
oxygen
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011533355A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012506453A5 (zh
JP2012506453A (ja
Inventor
リチャード エル． ワトソン，
リチャード エル． ワトソン，
アンソニー ビー． ウッド，
アンソニー ビー． ウッド，
グレゴリー ジェイ． アーチャンビュー，
グレゴリー ジェイ． アーチャンビュー，
Original Assignee
リバルシオ コーポレイション
リバルシオ コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/258,210 external-priority patent/US20090274730A1/en
Application filed by リバルシオ コーポレイション, リバルシオ コーポレイション filed Critical リバルシオ コーポレイション
Publication of JP2012506453A publication Critical patent/JP2012506453A/ja
Publication of JP2012506453A5 publication Critical patent/JP2012506453A5/ja
Application granted granted Critical
Publication of JP5688371B2 publication Critical patent/JP5688371B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
JP2011533355A 2008-10-22 2009-10-22 マトリクスメタロプロテイナーゼ９（ｍｍｐ９）媒介状態を治療するための組成物および方法 Expired - Fee Related JP5688371B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US10748008P 2008-10-22 2008-10-22
US10745308P 2008-10-22 2008-10-22
US61/107,480 2008-10-22
US61/107,453 2008-10-22
US12/258,210 2008-10-24
US12/258,210 US20090274730A1 (en) 2007-10-25 2008-10-24 Compositions and methods for treating inflammation
PCT/US2009/061744 WO2010048455A1 (en) 2008-10-22 2009-10-22 Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014246753A Division JP2015044868A (ja) 2008-10-22 2014-12-05 マトリクスメタロプロテイナーゼ９（ｍｍｐ９）媒介状態を治療するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2012506453A JP2012506453A (ja) 2012-03-15
JP2012506453A5 JP2012506453A5 (zh) 2012-12-06
JP5688371B2 true JP5688371B2 (ja) 2015-03-25

Family

ID=42119683

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2011533355A Expired - Fee Related JP5688371B2 (ja) 2008-10-22 2009-10-22 マトリクスメタロプロテイナーゼ９（ｍｍｐ９）媒介状態を治療するための組成物および方法
JP2011533341A Expired - Fee Related JP5688370B2 (ja) 2008-10-22 2009-10-22 胸腺間質性リンパ球新生因子（ｔｓｌｐ）媒介状態を治療するための組成物および方法
JP2014246760A Withdrawn JP2015044869A (ja) 2008-10-22 2014-12-05 胸腺間質性リンパ球新生因子（ｔｓｌｐ）媒介状態を治療するための組成物および方法
JP2014246753A Withdrawn JP2015044868A (ja) 2008-10-22 2014-12-05 マトリクスメタロプロテイナーゼ９（ｍｍｐ９）媒介状態を治療するための組成物および方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2011533341A Expired - Fee Related JP5688370B2 (ja) 2008-10-22 2009-10-22 胸腺間質性リンパ球新生因子（ｔｓｌｐ）媒介状態を治療するための組成物および方法
JP2014246760A Withdrawn JP2015044869A (ja) 2008-10-22 2014-12-05 胸腺間質性リンパ球新生因子（ｔｓｌｐ）媒介状態を治療するための組成物および方法
JP2014246753A Withdrawn JP2015044868A (ja) 2008-10-22 2014-12-05 マトリクスメタロプロテイナーゼ９（ｍｍｐ９）媒介状態を治療するための組成物および方法

Country Status (9)

Country Link
EP (2) EP2350263A4 (zh)
JP (4) JP5688371B2 (zh)
CN (2) CN102257130B (zh)
AU (2) AU2009308362B2 (zh)
BR (2) BRPI0920430A2 (zh)
CA (2) CA2741336A1 (zh)
IL (2) IL212277A0 (zh)
MX (2) MX2011004233A (zh)
WO (2) WO2010048455A1 (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6702949B2 (en) 1997-10-24 2004-03-09 Microdiffusion, Inc. Diffuser/emulsifier for aquaculture applications
CA2667634C (en) 2006-10-25 2016-07-12 Revalesio Corporation Mixing device and output fluids of same
JP5595041B2 (ja) 2006-10-25 2014-09-24 リバルシオ コーポレイション 酸素富化溶液を用いる、眼および他のヒト組織の治療処置の方法
US8445546B2 (en) 2006-10-25 2013-05-21 Revalesio Corporation Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
MX337862B (es) * 2008-04-28 2016-03-16 Revalesio Corp Composiciones y métodos para el tratamiento de la esclerosis multiple.
CN102076327B (zh) 2008-05-01 2014-04-16 利发利希奥公司 治疗消化功能紊乱的组合物和方法
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
BR112012028540A2 (pt) * 2010-05-07 2016-07-26 Revalesio Corp composições e métodos para melhorar desempenho fisiológico e tempo de recuperação
WO2012021856A1 (en) 2010-08-12 2012-02-16 Revalesio Corporation Compositions and methods for treatment of taupathy
BR112013026064A2 (pt) * 2011-04-13 2019-09-24 Revalesio Corp composições e métodos para inibir e/ou modular células t efetoras envolvidas em doença inflamatória neurodegenerativa
CN102250213B (zh) * 2011-07-01 2012-11-07 中国药科大学 基质金属蛋白酶-9多肽抑制剂3及其应用
CN102268070B (zh) * 2011-07-01 2012-11-28 中国药科大学 基质金属蛋白酶-9多肽抑制剂2及其应用
CN102268069B (zh) * 2011-07-01 2012-11-28 中国药科大学 基质金属蛋白酶-9多肽抑制剂4及其应用
KR101492435B1 (ko) * 2012-12-28 2015-02-10 고려대학교 산학협력단 ＨＩＦ­１α ｓｉＲＮＡ를 유효성분으로 함유하는 ＴＳＬＰ에 의해 매개되는 질환 예방 또는 치료용 약제학적 조성물
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
CN105477628B (zh) * 2014-09-19 2021-04-30 山东蓝金生物工程有限公司 抗癌组合物及其用途
CN106943593A (zh) * 2017-03-24 2017-07-14 浙江中医药大学 抗tslp抗体在制备防治慢性瘙痒药物中的应用
EP3645035A4 (en) * 2017-06-27 2021-04-07 Translational Sciences, Inc. INHIBITION OF VASCULAR MATRIX METALLOPROTEINASE 9 TO TREAT ISCHEMIC DAMAGE
CN114126623A (zh) * 2019-05-17 2022-03-01 宾夕法尼亚大学董事会 治疗肥胖和/或皮肤紊乱的方法和组合物
CN112876564B (zh) * 2019-11-29 2022-07-15 康诺亚生物医药科技（成都）有限公司 一种tslp相关病症治疗剂的开发和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69936453T2 (de) * 1998-07-28 2008-03-06 The Regents Of The University Of California, Oakland Für einen g-protein gekoppelten rezeptor, der an der empfindungstransduktion beteiligt ist, kodierende nukleinsäuren
CA2689694A1 (en) * 1999-07-21 2001-02-01 Omeros Corporation Solutions and methods for inhibition of pain, inflammation and cartilage degradation
US20040235732A1 (en) * 2000-11-03 2004-11-25 Qun-Yong Zhou Method for modulating angiogenesis using prokineticin receptor antagonists
US20030232114A1 (en) * 2002-06-13 2003-12-18 Nikola Dekleva Method for liquid enrichment with oxygen and applications of enriched liquids
WO2004022098A1 (en) * 2002-09-09 2004-03-18 Borsos Ferenc Oxygen-enriched water, treated within a magnetic field and heavy water
US20070077553A1 (en) * 2003-10-30 2007-04-05 Rosetta Genomics Bioinformatically detectable group of novel vaccinia regulatory genes and uses thereof
WO2004071436A2 (en) * 2003-02-10 2004-08-26 Thomas Jefferson University The use of gcc ligands
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US7393924B2 (en) * 2004-01-06 2008-07-01 Franco Vitaliano Smart bio-nanoparticle elements
KR100583430B1 (ko) * 2004-03-08 2006-05-24 양경숙 차륜 가변형 스쿠터
US20050249712A1 (en) * 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
WO2008018932A2 (en) * 2006-05-01 2008-02-14 The Board Of Trustees Of The Leland Stanford Junior University Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury
EP2043611A2 (en) * 2006-06-30 2009-04-08 Nucryst Pharmaceuticals Corp. Metal-containing formulations and methods of use
CA2667634C (en) * 2006-10-25 2016-07-12 Revalesio Corporation Mixing device and output fluids of same
JP5491185B2 (ja) * 2006-10-25 2014-05-14 リバルシオ コーポレイション 傷のケアおよび処置の方法
JP5595041B2 (ja) * 2006-10-25 2014-09-24 リバルシオ コーポレイション 酸素富化溶液を用いる、眼および他のヒト組織の治療処置の方法
AU2008316794B2 (en) * 2007-10-25 2015-04-23 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
MX337862B (es) * 2008-04-28 2016-03-16 Revalesio Corp Composiciones y métodos para el tratamiento de la esclerosis multiple.

Also Published As

Publication number Publication date
MX2011004235A (es) 2011-06-24
AU2009308362A1 (en) 2010-04-29
MX2011004233A (es) 2011-06-24
CN102257130A (zh) 2011-11-23
EP2350263A4 (en) 2013-07-03
CA2741336A1 (en) 2010-04-29
CN102256607B (zh) 2014-11-05
EP2364154A1 (en) 2011-09-14
IL212309A0 (en) 2011-06-30
CA2741341A1 (en) 2010-04-29
WO2010048455A1 (en) 2010-04-29
AU2009308302A1 (en) 2010-04-29
CN102256607A (zh) 2011-11-23
JP2015044869A (ja) 2015-03-12
CN102257130B (zh) 2016-07-06
BRPI0920430A2 (pt) 2019-09-24
WO2010048425A1 (en) 2010-04-29
IL212277A0 (en) 2011-06-30
IL212309A (en) 2016-04-21
JP2015044868A (ja) 2015-03-12
AU2009308362B2 (en) 2016-02-04
JP2012506451A (ja) 2012-03-15
EP2364154A4 (en) 2013-07-10
JP5688370B2 (ja) 2015-03-25
EP2350263A1 (en) 2011-08-03
MX337035B (es) 2016-02-09
BRPI0920201A2 (pt) 2019-09-10
JP2012506453A (ja) 2012-03-15
AU2009308302B2 (en) 2016-01-21

Similar Documents

Publication Publication Date Title
JP5688371B2 (ja) マトリクスメタロプロテイナーゼ９（ｍｍｐ９）媒介状態を治療するための組成物および方法
US20100098659A1 (en) Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions
JP5869612B2 (ja) 多発性硬化症を治療するための組成物および方法
JP5750540B2 (ja) 喘息および他の肺障害を治療するための組成物および方法
US9523090B2 (en) Compositions and methods for treating inflammation
US10125359B2 (en) Compositions and methods for treating inflammation
US20100098687A1 (en) Compositions and methods for treating thymic stromal lymphopoietin (tslp)-mediated conditions
US20100004189A1 (en) Compositions and methods for treating cystic fibrosis
US20100008997A1 (en) Compositions and methods for treating asthma and other lung disorders
US20090274771A1 (en) Compositions and methods for treating asthma and other lung disorders
US20120114702A1 (en) Compositions and methods for treating asthma and other lung disorders
WO2010062628A1 (en) Compositions and methods for treating asthma and other lung disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121022

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121022

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140403

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140707

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141205

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20141222

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150119

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150126

R150 Certificate of patent or registration of utility model

Ref document number: 5688371

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees